Last month, Biopharm joined hundreds of exhibitors and thousands of visitors in attending Interphex Japan. The Tokyo-based tradeshow and conference covers the whole process of pharmaceuticals R&D and manufacturing.
On the first day, Mark Bamforth, CEO of Gallus Pharmaceuticals, gave a keynote presentation on “The Executive’s Dilemma: the Make vs Buy Decision”. During his session, it was great to hear him reference our recent whitepaper “Mab Manufacturing Today and Tomorrow”.
Walking the exhibit floor, we saw all kinds of technology developers showing off their latest technologies. Some were familiar to us, but there were also many new technologies that were completely new to us!
One interesting product we encountered was Pall’s new Allegro 200L single-use mixer with baffles for efficient mixing. The new Octet Assay Systems from ForteBio wowed us with its innovative use of new biosensor technologies, and we weren’t the only ones as other delegates gathered around the booth to learn more.
Another interesting technology we saw came from Taiwanese company, CESCO Bioproducts, who were showing a new and very interesting technology. The company introduced a bench-top/lab-scale bioreactor system called BelloCell, which provides low shear stress, high aeration, and a foam-free & 3-D culture environment, enabling cultures to achieve high cell density.
During our visit to Interphex, we were kindly invited to attend Merck Millipore’s new bioprocess training center in Daiba, which had been specially opened for visitors during the show. As the proverb goes, “One look is worth a thousand words” and ss we were shown around this impressive new training centre, you could really start to see that the bioprocess industry in Japan is on the rise.
The center’s official launch will be at the Merck Millipore BioForum in September, where Biopharm CEO, Andrew Sinclair, will be presenting a session entitled “The Role of Single Use Technologies to Reduce Risk in the Facility of the Future”.